Skip to main content
Vinod P. Balachandran on Muck Rack

Vinod P. Balachandran

As seen in: Nature, Verywell Health, HemOnc Today, Archives of Pathology, Targeted Oncology, Tiger Sniff
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Vinod P.

Contact Vinod P., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Pancreatic cancer - Nature Reviews Disease Primers

|
By Susanne Roth, Minoti V. Apte, Vinod P. Balachandran, Giulia Biffi, Thierry Conroy, Edna Cukierman, Efrat Dotan, Irene Esposito, Barbara Grünwald, Alison Klein, Nuria Malats, Mike J. Pishvaian, Francisco X. Real, Dieter Saur, Jens T Siveke, Christoph W Michalski, Miriam Klauß, Eileen M. O´Reilly
| Nature Verified
Abstract Pancreatic ductal adenocarcinoma remains one of the deadliest malignancies, characterized by late diagnosis, aggressive biology and limited therapeutic success. Advances in multiagent chemotherapy have improved outcomes across disease stages, whereas precision medicine approaches are reshaping treatment paradigms. Personalized RNA vaccines and oncogenic KRAS-directed agents represent emerging immunological and molecular frontiers.
Open in Who Shared Issue with article?

胰腺癌mRNA疫苗6年随访：应答者生存率近90%，这一强效信号意味着什么？-虎嗅网

|
By Vinod P. Balachandran
| Tiger Sniff
胰腺癌患者的五年生存率只有13%。而在一项小规模I期临床试验里，接受个性化mRNA新抗原疫苗治疗并产生免疫应答的8名患者中，近90%在六年后仍然存活。这组数字，在2026年AACR年会上引发了广泛关注。 BioNTech挑战癌症之王，I期结果登Nature BioNTech启动针对胰腺导管腺癌mRNA个性化新抗原疗法2期试验 从"免疫沙漠"到持久T细胞 胰腺癌在肿瘤免疫治疗领域长期被视为"烫手山芋"。传统免疫检查点抑制剂在绝大多数实体瘤中已取得突破，但在胰腺癌这里几乎宣告失败——肿瘤微环境极度抑制，突变负荷低，原发性免疫浸润稀少，几乎不给免疫系统任何施展空间。行业内一度的共识是：胰腺癌患者根本无法对肿瘤产生有效免疫应答。 纪念斯隆-凯特琳癌症中心（MSK）的Vinod...
Open in Who Shared Issue with article?

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

|
By Wungki Park, Catherine A. O’Connor, Joanne F. Chou, Marc Hilmi, Zeynep Tarcan, Carly Schwartz, Mary Larsen Verified, Karthigayini Sivaprakasam, Shigeaki Umeda, Maria Perry, Anna Varghese, Fiyinfolu Balogun, Alice Zervoudakis, Seth Katz, Tae-Hyung Kim, Ken Zhao, Allison Richards, Nicolas Lecomte, Daniel Muldoon, Walid K. Chatila, Jessica Yang, Devika Rao Verified, Smita Joshi, Michael Foote, James Harding Verified, Andrew Epstein, David P. Kelsen, Fergus Keane, Joshua D. Schoenfeld, Anupriya Singhal, Erin DiGuglielmo, Chaitanya Bandlamudi, Junmin Song, Haochen Zhang, Maria Teresa Lao, Jerry P Melchor, Ronak Shah, Wenfei Kang, Francesca Mazzoni, Kevin C. Soares, Ernesto Santos, Vineet S. Rolston, Marsha Reyngold, Alice Wei, Murray J. Tipping, Olca Basturk, Michael Berger, Mark Schattner, William R. Jarnagin, Nadeem Riaz, Vinod P. Balachandran, Dana Pe’er, Marinela Capanu, Eileen M. O’Reilly, Ramzi Homsi, Elias Karnoub, Imane El-Dika, Ryan Sugarman, Sree Chalassani, Hulya Sahin Ozkan, Junguei Hong, Agustin III Cardenas, Mark TA Donoghue, Richard Kihn Do, Christine Iacobuzio-Donahue
| Nature Verified
Abstract Homologous recombination deficiency (HRD) arising from BRCA1or BRCA2 or PALB2 mutations confers sensitivity to platinum chemotherapy and PARP inhibition in pancreatic cancer (PC) and may enable prolonged disease control with immune checkpoint blockade (ICB). The phase 2 POLAR trial evaluated maintenance pembrolizumab plus olaparib following platinum-based chemotherapy in biomarker-stratified metastatic PC.
Open in Who Shared Issue with article?
See all 14 licensed articles (16 Total)